Pilot experience of [ 161 Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry
Theranostics · 2025
DOI: 10.7150/thno.115831 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Theranostics, 2025. Verfasst von Florian Rosar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, Germany. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Prostatic Neoplasms, Castration-Resistant, Radioisotopes. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, Germany.
Zitieren
APA
Rosar, F., Burgard, C., Petrescu, C., Blickle, A., Bartholomä, M., Maus, S., Bastian, M. B., Speicher, T., Schaefer-Schuler, A., & Ezziddin, S. (2025). Pilot experience of [ 161 Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry. Theranostics. https://doi.org/10.7150/thno.115831
Vancouver
Rosar F, Burgard C, Petrescu C, Blickle A, Bartholomä M, Maus S, et al. Pilot experience of [ 161 Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry. Theranostics. 2025. doi:10.7150/thno.115831
BibTeX
@article{Rosar2025,
author = {Rosar, Florian and Burgard, Caroline and Petrescu, Christine and Blickle, Arne and Bartholomä, Mark and Maus, Stephan and Bastian, Moritz B and Speicher, Tilman and Schaefer-Schuler, Andrea and Ezziddin, Samer},
title = {Pilot experience of [ 161 Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry},
journal = {Theranostics},
year = {2025},
doi = {10.7150/thno.115831}
}
EUVIMED